466 related articles for article (PubMed ID: 30030591)
1. Inhibition of protein misfolding and aggregation by natural phenolic compounds.
Dhouafli Z; Cuanalo-Contreras K; Hayouni EA; Mays CE; Soto C; Moreno-Gonzalez I
Cell Mol Life Sci; 2018 Oct; 75(19):3521-3538. PubMed ID: 30030591
[TBL] [Abstract][Full Text] [Related]
2. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade.
Chiti F; Dobson CM
Annu Rev Biochem; 2017 Jun; 86():27-68. PubMed ID: 28498720
[TBL] [Abstract][Full Text] [Related]
3. Misfolded protein aggregates: mechanisms, structures and potential for disease transmission.
Moreno-Gonzalez I; Soto C
Semin Cell Dev Biol; 2011 Jul; 22(5):482-7. PubMed ID: 21571086
[TBL] [Abstract][Full Text] [Related]
4. Non-polyphenolic natural inhibitors of amyloid aggregation.
Ma L; Yang C; Zheng J; Chen Y; Xiao Y; Huang K
Eur J Med Chem; 2020 Apr; 192():112197. PubMed ID: 32172082
[TBL] [Abstract][Full Text] [Related]
5. Protein misfolding and related human diseases: A comprehensive review of toxicity, proteins involved, and current therapeutic strategies.
Khan AN; Khan RH
Int J Biol Macromol; 2022 Dec; 223(Pt A):143-160. PubMed ID: 36356861
[TBL] [Abstract][Full Text] [Related]
6. Prion-Like Protein Aggregates and Type 2 Diabetes.
Mukherjee A; Soto C
Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28159831
[TBL] [Abstract][Full Text] [Related]
7. Type 2 diabetes as a protein misfolding disease.
Mukherjee A; Morales-Scheihing D; Butler PC; Soto C
Trends Mol Med; 2015 Jul; 21(7):439-49. PubMed ID: 25998900
[TBL] [Abstract][Full Text] [Related]
8. Unravelling protein aggregation as an ageing related process or a neuropathological response.
Trigo D; Nadais A; da Cruz E Silva OAB
Ageing Res Rev; 2019 May; 51():67-77. PubMed ID: 30763619
[TBL] [Abstract][Full Text] [Related]
9. Animal models for prion-like diseases.
Fernández-Borges N; Eraña H; Venegas V; Elezgarai SR; Harrathi C; Castilla J
Virus Res; 2015 Sep; 207():5-24. PubMed ID: 25907990
[TBL] [Abstract][Full Text] [Related]
10. Rutin suppresses human-amylin/hIAPP misfolding and oligomer formation in-vitro, and ameliorates diabetes and its impacts in human-amylin/hIAPP transgenic mice.
Aitken JF; Loomes KM; Riba-Garcia I; Unwin RD; Prijic G; Phillips AS; Phillips ARJ; Wu D; Poppitt SD; Ding K; Barran PE; Dowsey AW; Cooper GJS
Biochem Biophys Res Commun; 2017 Jan; 482(4):625-631. PubMed ID: 27865831
[TBL] [Abstract][Full Text] [Related]
11. [Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis].
Yoshida K; Higuchi K; Ikeda S
Brain Nerve; 2012 Jun; 64(6):665-74. PubMed ID: 22647474
[TBL] [Abstract][Full Text] [Related]
12. Spectral Fluorescence Pathology of Protein Misfolding Disorders.
Stepanchuk AA; Stys PK
ACS Chem Neurosci; 2024 Mar; 15(5):898-908. PubMed ID: 38407017
[TBL] [Abstract][Full Text] [Related]
13. Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers.
Ugalde CL; Finkelstein DI; Lawson VA; Hill AF
J Neurochem; 2016 Oct; 139(2):162-180. PubMed ID: 27529376
[TBL] [Abstract][Full Text] [Related]
14. Protein folding and aggregation into amyloid: the interference by natural phenolic compounds.
Stefani M; Rigacci S
Int J Mol Sci; 2013 Jun; 14(6):12411-57. PubMed ID: 23765219
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases.
Cheng B; Gong H; Xiao H; Petersen RB; Zheng L; Huang K
Biochim Biophys Acta; 2013 Oct; 1830(10):4860-71. PubMed ID: 23820032
[TBL] [Abstract][Full Text] [Related]
16. Protein misfolding, aggregation and mechanism of amyloid cytotoxicity: An overview and therapeutic strategies to inhibit aggregation.
Zaman M; Khan AN; Wahiduzzaman ; Zakariya SM; Khan RH
Int J Biol Macromol; 2019 Aug; 134():1022-1037. PubMed ID: 31128177
[TBL] [Abstract][Full Text] [Related]
17. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
[TBL] [Abstract][Full Text] [Related]
18. Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena.
Pain C; Dumont J; Dumoulin M
Biochimie; 2015 Apr; 111():82-106. PubMed ID: 25656912
[TBL] [Abstract][Full Text] [Related]
19. Thermodynamic and kinetic approaches for drug discovery to target protein misfolding and aggregation.
Vendruscolo M
Expert Opin Drug Discov; 2023; 18(8):881-891. PubMed ID: 37276120
[TBL] [Abstract][Full Text] [Related]
20. A review on protein misfolding, aggregation and strategies to prevent related ailments.
Shamsi TN; Athar T; Parveen R; Fatima S
Int J Biol Macromol; 2017 Dec; 105(Pt 1):993-1000. PubMed ID: 28743576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
